Receptor Binding

How Receptor Binding Works

Receptor binding follows a specific sequence:

1. Recognition - Peptide approaches receptor through diffusion
2. Binding - Complementary shapes and charges enable attachment
3. Conformational change - Receptor structure changes upon binding
4. Signal transduction - Intracellular signaling pathways activate
5. Cellular response - Changes in cell metabolism, gene expression, or function
6. Dissociation - Peptide eventually releases, ending signal

The lock-and-key (or induced fit) model describes how specific molecular shapes enable selective binding.

Relevance to Peptides

Receptor binding is fundamental to peptide mechanism of action:

Peptide Receptor Examples

Peptide	Target Receptor	Receptor Type	Effect
Semaglutide	GLP-1R	GPCR	Glucose regulation, satiety
Tirzepatide	GLP-1R + GIPR	GPCRs	Dual incretin activation
Ipamorelin	GHS-R1a	GPCR	GH release
PT-141	MC4R	GPCR	Sexual function
BPC-157	Multiple proposed	Various	Tissue repair

Selectivity and Specificity

Peptide selectivity determines side effect profiles:

• Ipamorelin - Highly selective for GHS-R, minimal cortisol/prolactin effects
• GHRP-6 - Less selective, activates hunger and cortisol pathways
• Melanotan II - Activates multiple melanocortin receptors (less selective)

Binding Characteristics

Binding Affinity (Kd)

Affinity	Kd Range	Interpretation
Very high	Under 1 nM	Strong binding, potent
High	1-10 nM	Good binding
Moderate	10-100 nM	Moderate binding
Low	Over 100 nM	Weak binding

Lower Kd = higher affinity = tighter binding

Efficacy vs Affinity

Two key concepts in receptor pharmacology:

Affinity - How tightly a peptide binds to its receptor Efficacy - How well binding activates the receptor

A peptide can have high affinity but low efficacy (partial agonist) or vice versa.

Receptor Types

G-Protein Coupled Receptors (GPCRs)

Most common peptide targets:

• Seven-transmembrane domain structure
• Activate G-proteins when bound
• Examples: GLP-1R, GHS-R, melanocortin receptors

Receptor Tyrosine Kinases (RTKs)

Growth factor receptors:

• Single-pass transmembrane proteins
• Activate kinase signaling
• Example: Insulin receptor, IGF-1R

Nuclear Receptors

Some peptide-influenced pathways:

• Intracellular receptors
• Affect gene transcription directly
• Usually steroid hormone targets, but some peptide connections

Agonists, Antagonists, and Modulators

Type	Receptor Effect	Example
Full agonist	Maximum activation	Semaglutide at GLP-1R
Partial agonist	Submaximal activation	Some GHRP variants
Antagonist	Blocks receptor	Certain research compounds
Inverse agonist	Reduces baseline activity	Some GPCR ligands
Allosteric modulator	Changes response to other ligands	Research compounds

Multi-Receptor Peptides

Some peptides bind multiple receptors:

Tirzepatide (GLP-1 + GIP)

• Designed as dual agonist
• Activates both incretin receptors
• Enhanced weight loss vs single-target GLP-1 agonists

Retatrutide (GLP-1 + GIP + Glucagon)

• Triple receptor agonist
• Activates three metabolic receptors
• Research shows enhanced effects

Melanotan II

• Activates multiple melanocortin receptors (MC1R-MC5R)
• Causes tanning, appetite suppression, sexual effects
• Less selective than PT-141 (MC4R-focused)

Measuring Receptor Binding

Assay	What It Measures	Application
Radioligand binding	Kd, Bmax	Affinity, receptor density
SPR (Surface Plasmon Resonance)	Kon, Koff, Kd	Binding kinetics
Functional assays	EC50, Emax	Activation potency, efficacy
Computational docking	Predicted binding	Drug design

Frequently Asked Questions

Why do some peptides have fewer side effects than others?

Selectivity. Peptides that bind only to their intended receptor (like ipamorelin at GHS-R) produce fewer off-target effects than peptides that activate multiple receptors. GHRP-6 activates additional pathways causing hunger and cortisol effects that ipamorelin avoids.

Can receptors become desensitized to peptides?

Yes. Continuous receptor activation can lead to downregulation (fewer receptors) or desensitization (reduced response). This is why some protocols use intermittent dosing. However, the degree of desensitization varies significantly among receptor types.

What determines peptide potency?

Potency depends on both binding affinity and efficacy. A peptide needs to bind tightly enough (affinity) and activate the receptor sufficiently (efficacy). Additionally, pharmacokinetics (how long the peptide stays in the body) affects apparent potency.

How do multi-agonist peptides work?

Multi-agonists like tirzepatide are designed with structural features that enable binding to multiple related receptors. The peptide sequence includes elements recognized by each target receptor. This allows additive or synergistic effects through complementary pathways.